FDA Panel OKs 6 Longevity Peptides for Compounding, Vanta Advances Biotech Strategy
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.